<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALREX - loteprednol etabonate suspension/ drops </strong><br>STAT Rx USA LLC<br></p></div>
<h1>ALREX <br>loteprednol etabonate ophthalmic suspension, 0.2%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b9ea28d7-37ec-418f-beb7-54c3614c6c05"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ALREX® (loteprednol etabonate ophthalmic suspension) contains a sterile, topical anti-inflammatory corticosteroid for ophthalmic use.</p>
<p>Loteprednol etabonate is a white to off-white powder.</p>
<p>Loteprednol etabonate is represented by the following structural formula:</p>
<div class="Figure"><img alt="Loteprednol etabonate (Structural formula)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf290d54-26a1-4d22-8cb8-852bdc7b5280&amp;name=0f4e4ac8-189c-477f-ba85-8261d8765d02-01.jpg"></div>
<p>C<span class="Sub">24</span>H<span class="Sub">31</span>ClO<span class="Sub">7</span><br>Mol. Wt. 466.96</p>
<p>Chemical Name:</p>
<p>chloromethyl 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate</p>
<p><span class="Bold">Each mL contains:</span></p>
<p>ACTIVE: Loteprednol Etabonate 2 mg (0.2%);</p>
<p>INACTIVES: Edetate Disodium, Glycerin, Povidone, Purified Water and Tyloxapol. Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust the pH to 5.4-5.5. The suspension is essentially isotonic with a tonicity of 250 to 310 mOsmol/kg.</p>
<p>PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_17cf6aea-a5ab-4b08-bbdd-e4769a03d72b"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> formation associated with <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids.</p>
<p>However, corticosteroids are thought to act by the induction of phospholipase A<span class="Sub">2</span> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<span class="Sub">2</span>. Corticosteroids are capable of producing a rise in intraocular pressure.</p>
<p>Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon <span class="Italics">in vivo </span>and <span class="Italics">in</span><span class="Italics"> vitro </span>preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites.</p>
<p>Results from a bioavailability study in normal volunteers established that plasma levels of loteprednol etabonate and Δ<span class="Sup">1</span> cortienic acid etabonate (PJ 91), its primary, inactive metabolite, were below the limit of quantitation (1 ng/mL) at all sampling times. The results were obtained following the ocular administration of one drop in each eye of 0.5% loteprednol etabonate 8 times daily for 2 days or 4 times daily for 42 days. This study suggests that limited (&lt;1 ng/mL) systemic absorption occurs with ALREX.</p>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_cd657636-a473-403d-9224-0639e76adf1e"></a><a name="section-2.1"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">In two double-masked, placebo-controlled six-week environmental studies of 268 patients with seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, ALREX, when dosed four times per day was superior to placebo in the treatment of the signs and symptoms of seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
<p>ALREX provided reduction in bulbar <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival injection</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, beginning approximately 2 hours after instillation of the first dose and throughout the first 14 days of treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b4bfe726-651a-4046-9c5f-87d1fac8ad00"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ALREX Ophthalmic Suspension is indicated for the temporary relief of the signs and symptoms of seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7ae5ef00-cba1-4524-b5a0-ab8542135e1b"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ALREX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures. ALREX is also contraindicated in individuals with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients of this preparation and to other corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e6d3a791-835e-4e84-b1fa-09a41e684856"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. Steroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex).</p>
<p>Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_739886b5-a373-4fe7-8fe7-24f4999b3549"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_9e444841-febb-4452-932f-201aac32d5e7"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">For ophthalmic use only. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.</p>
<p>If signs and symptoms fail to improve after two days, the patient should be re-evaluated.</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be monitored.</p>
<p><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_035e04d9-0ec2-4c06-a522-7d60997a8d7b"></a><a name="section-6.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">This product is sterile when packaged. Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the suspension. If <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> becomes aggravated, the patient should be advised to consult a physician.</p>
<p>Patients should be advised not to wear a contact lens if their eye is red. ALREX should not be used to treat contact lens related irritation.</p>
<p>The preservative in ALREX, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses <span class="Bold">and </span><span class="Bold">whose eyes are not red</span>, should be instructed to wait at least ten minutes after instilling ALREX before they insert their contact lenses.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_26d8d334-9878-440c-be0f-44bbf05f0c39"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long-term animal studies have not been conducted to evaluate the carcinogenic potential of loteprednol etabonate. Loteprednol etabonate was not genotoxic <span class="Italics">in vitro </span>in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> tk assay, or in a chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, or <span class="Italics">in vivo </span>in the single dose mouse micronucleus assay. Treatment of male and female rats with up to 50 mg/kg/day and 25 mg/kg/day of loteprednol etabonate, respectively, (1500 and 750 times the maximum clinical dose, respectively) prior to and during mating did not impair fertility in either gender.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b31e3638-ac10-490e-915c-9315861e80ea"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_5e7c367c-6227-40a0-8d7c-4942ef9e9d61"></a><a name="section-6.4.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First">Pregnancy Category C. Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of <span class="product-label-link" type="condition" conceptid="4062639" conceptname="Meningocele">meningocele</span>, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (85 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (15 times the maximum daily clinical dose). Oral treatment of rats during organogenesis resulted in <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> (absent innominate artery at ≥5 mg/kg/day doses, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span> at ≥50 mg/kg/day) and embryotoxicity (increased postimplantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥50 mg/kg/day). Treatment of rats with 0.5 mg/kg/day (15 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity. Loteprednol etabonate was maternally toxic (significantly reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> during treatment) when administered to pregnant rats during organogenesis at doses of ≥5 mg/kg/day.</p>
<p>Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; the NOEL for these effects was 5 mg/kg/day. Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period.</p>
<p>There are no adequate and well controlled studies in pregnant women. ALREX Ophthalmic Suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_c83c9793-2a76-44be-bf4b-db4a5772decd"></a><a name="section-6.5"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when ALREX is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_40e6d42c-59af-492a-82dd-e81de940691c"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_2ffb5349-39fb-4b7e-b076-9c085aa4336e"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, visual acuity and field defects, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation, secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>/blurring, burning on instillation, <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">chemosis</span>, discharge, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">epiphora</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, injection, and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>. Other ocular adverse reactions occurring in less than 5% of patients include <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, corneal abnormalities, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, ocular irritation/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, papillae, and <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>. Some of these events were similar to the underlying ocular disease being studied.</p>
<p>Non-ocular adverse reactions occurred in less than 15% of patients. These include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.</p>
<p>In a summation of controlled, randomized studies of individuals treated for 28 days or longer with loteprednol etabonate, the incidence of significant elevation of intraocular pressure (≥10 mm Hg) was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients receiving 1% prednisolone acetate and 0.5% (3/583) among patients receiving placebo. Among the smaller group of patients who were studied with ALREX, the incidence of clinically significant increases in IOP (≥10 mm Hg) was 1% (1/133) with ALREX and 1% (1/135) with placebo.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d5b9f516-3f90-4c89-92a1-4de2c7b1cc94"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">SHAKE VIGOROUSLY BEFORE USING.</p>
<p>One drop instilled into the affected eye(s) four times daily.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_62aa9211-4904-46a4-a41f-af6e9d447b9b"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ALREX® (loteprednol etabonate ophthalmic suspension, 0.2%) is supplied in a plastic bottle with a controlled drop tip in the following sizes:</p>
<p></p>
<p>5 mL  -  NDC # 16590-007-05</p>
<p></p>
<p><span class="Bold">DO NOT USE IF NECKBAND IMPRINTED WITH "Protective Seal" AND YELLOW IS NOT INTACT.</span></p>
<p><span class="Bold"></span></p>
<p><span class="Bold">Relabeling and Repackaging by:</span></p>
<p><span class="Bold"></span>STAT Rx USA LLC</p>
<p><span>Gainesville, GA  30501</span></p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_866bb864-6131-4065-82ee-78c883786be5"></a><a name="section-10"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store upright between 15°–25°C (59°–77°F). DO NOT FREEZE.</p>
<p>KEEP OUT OF REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbe21375-6762-44f3-9b90-984279f5cf9a"></a><a name="section-11"></a><p></p>
<h1>MANUFACTURER INFORMATION</h1>
<p class="First">Bausch &amp; Lomb Incorporated, Tampa, Florida 33637</p>
<p>U.S. Patent No. 4,996,335<br>U.S. Patent No. 5,540,930 <br>U.S. Patent No. 5,747,061</p>
<p>©Bausch &amp; Lomb Incorporated<br>Alrex® is a registered trademark of Bausch &amp; Lomb Incorporated</p>
<p>Revised August 2008</p>
<p>9007902 (Folded)<br>9005502 (Flat)</p>
<p></p>
<p><span class="Bold">Relabeling and Repackaging by:</span></p>
<p>STAT Rx USA LLC</p>
<p>Gainesville, GA  30501</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L0b9d19f5-69cd-40c0-b197-d565c240a393"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL - ALREX OPTH SUSP - 0.2%, 5 mL</h1>
<p class="First"><img alt="ALREX OPTH SUSP LABEL Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cf290d54-26a1-4d22-8cb8-852bdc7b5280&amp;name=ALREX%20OPTH%20SUSP%20LABEL.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALREX 		
					</strong><br><span class="contentTableReg">loteprednol etabonate suspension/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-007(NDC:24208-353)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LOTEPREDNOL ETABONATE</strong> (LOTEPREDNOL) </td>
<td class="formItem">LOTEPREDNOL ETABONATE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TYLOXAPOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-007-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020803</td>
<td class="formItem">03/09/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT Rx USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PSS World Medical Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT Rx USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel(16590-007), repack(16590-007)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>46d7d49a-d8e8-40a4-9148-728e8c1805fb</div>
<div>Set id: cf290d54-26a1-4d22-8cb8-852bdc7b5280</div>
<div>Version: 2</div>
<div>Effective Time: 20120918</div>
</div>
</div> <div class="DistributorName">STAT Rx USA LLC</div></p>
</body></html>
